Mandate

Vinge advises Oberthur Technologies in public offer for XPonCard

February 27, 2008

Vinge is advising Oberthur Technologies in connection with its announced public offer for XPonCard Group AB (publ). The offer, which comprises all shares in XPonCard, values XPonCard at approximately SEK 704 million.

The Vinge team advising Oberthur Technologies S.A. includes Anders Åberg, Jan Lombach, Mattias Friberg and Petter Elmstedt. Paula Röttorp, Louise Salomon and Anders Morén are providing advice regarding the financing, and Mattias Schömer and Johan Bocander are providing tax advice. Emma Dufva is providing competition law advice.

Oberthur Technologies is listed on Euronext Paris. Oberthur Technologies is one of the world leaders in the field of secure technologies in its main target markets: smart cards, secure printing and cash protection. XPonCard is a services company listed on OMX Nordic Exchange Stockholm that provides card concepts and solutions for secure payment, smart mobile solutions, improved customer loyalty and secure identification. The combination of Oberthur Technologies and XPonCard will create the second largest player in the global smart card industry with sales in the order of EUR 735 million (SEK 6.8 billion).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025